EVH — Evolent Health, Inc.

Evolent Health (EVH) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $469 million, exceeding the midpoint of guidance.
• Adjusted EBITDA: $37.8 million, also above guidance expectations.
• 2025 Full-Year Revenue: $1.77 billion (adjusted for ACO divestiture).
• Medical Expense Ratio (MER): 89% for 2025 (excluding Evolent Care Partners), with Q4 MER at 95% due to true-ups.
• Net Debt: $782 million, below the expected range of $805 million to $840 million.

2. Strategic Updates and Business Highlights

• Evolent is experiencing strong organic growth, with a forecasted revenue increase of approximately 30% for 2026, targeting $2.5 billion at the midpoint.
• The company is shifting its focus towards oncology, expecting 65% of revenue to come from this segment in 2026, up from 36% in 2025.
• Approximately 90% of Performance Suite revenue has transitioned to a new enhanced model, which includes downside protections and revenue rate adjustments.
• Evolent has successfully signed two major new customers under the enhanced Performance Suite model and retained all key customers.
• The company is leveraging AI and automation to enhance operational efficiency, achieving over $20 million in annualized savings in Q4 2025.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: $2.4 billion to $2.6 billion, driven by new Performance Suite launches.
• Adjusted EBITDA Guidance: $110 million to $140 million, with expectations of a significant ramp-up in the second half of the year.
• The company anticipates that the first half of 2026 will face challenges due to exchange membership declines and conservative reserving for new contracts, but expects a strong recovery in the latter half.

4. Bad News, Challenges, or Points of Concern

• Exchange Membership Declines: A significant headwind, with an anticipated $40 million impact on revenue due to membership losses and plan closures.
• Conservative Reserving Approach: The new contracts are being reserved at a higher MER of 103%, which could temporarily affect profitability.
• Medical Expense Ratio (MER) Increase: Expected to rise to approximately 93% in 2026 due to new business and reserving methodologies.
• Churn in Administrative Services: Notable churn from one customer who in-sourced services after being acquired, impacting revenue.

5. Notable Q&A Insights

• Management emphasized the conservative approach to reserving for new contracts, which is standard practice and reflects the initial uncertainty in data flow and claims.
• The company is optimistic about the oncology cost trends, expecting them to remain stable in 2026, similar to 2025.
• There is a strong pipeline of potential contracts, with a balanced mix between Performance Suite and Tech & Services, but no immediate new contracts expected to impact 2026 negatively.
• Management highlighted the importance of the enhanced contract structure, which provides downside protections and aims to create long-term value despite short-term pressures.

Overall, Evolent Health's Q4 2025 results reflect strong performance and strategic positioning, particularly in oncology, despite facing challenges related to membership declines and conservative financial practices. The outlook for 2026 remains cautiously optimistic, with expectations for significant growth and operational improvements.